Redhill Biopharma Ltd
NASDAQ:RDHL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Boss Energy Ltd
XBER:B8Y
|
AU |
|
B
|
Bewith Inc
TSE:9216
|
JP |
|
S
|
Synthesis Energy Systems Inc
XBER:3KB
|
US |
Redhill Biopharma Ltd
Inventory
Redhill Biopharma Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Inventory
$3.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Inventory
$3.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Inventory
$1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Inventory
$4.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Inventory
₪96.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Redhill Biopharma Ltd
Glance View
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.
See Also
What is Redhill Biopharma Ltd's Inventory?
Inventory
3.2m
USD
Based on the financial report for Jun 30, 2025, Redhill Biopharma Ltd's Inventory amounts to 3.2m USD.
What is Redhill Biopharma Ltd's Inventory growth rate?
Inventory CAGR 5Y
-8%
Over the last year, the Inventory growth was -17%. The average annual Inventory growth rates for Redhill Biopharma Ltd have been -35% over the past three years , -8% over the past five years .
